Ethypharm – Beyond our medicines, lives

Beyond our medecines, lives

Ethypharm is a specialty pharmaceutical company with European roots, focused on specific Central Nervous System (CNS) diseases and conditions, and on adding value to medicines used in Critical Care situations.

Discover Ethypharm at a glance
Ethypharm HomePage

A commitment to the patients we serve

Many of our products are indicated for sensitive situations in which patients either suffer from debilitating conditions such as chronic pain or addiction, or are in a critical state.
All around the world, Ethypharm employees are engaged daily to make the difference for patients’ lives by ensuring that people in need are able to receive the right treatment at the right time and with the right support.

Read more on our commitments

Adding value in CNS and Critical Care

Ethypharm is deeply engaged in the CNS and Critical Care areas, where our medicines treat patients today and our teams work on innovative solutions for tomorrow. Willing to grow beyond our recognised positions in the treatment of severe pain and opioid dependency, we are constantly screening opportunities in search for those which will respond to unmet needs in our 2 core therapeutic areas.

CNS at Ethypharm Critical Care at Ethypharm

A Group on a dynamic development journey

Ethypharm is a rapidly transforming company, with a clear strategy and significant growth ambition. Our teams are constantly looking for opportunities to develop our product portfolio, selectively enlarge our geographical coverage and enrich our development pipeline. We are extremely open to discussing potential partnerships. Get to know our R&D and business development (BD) teams and come discuss with us!

R&D at Ethypharm BD at Ethypharm

Ethypharm Join Us

Ethypharm's latest news

Ethypharm announces its 1st rare disease partnership in China

On 10 November 2020, Ethypharm and Laboratoires CTRS announced that they have signed an exclusive agreement for the registration and commercialisation in the People’s Republic of China of an orphan medicine indicated for the treatment of patients with rare inborn errors in primary bile acid synthesis.

Read the full press release in our newsroom
NB: By clicking on this link, you will be redirected to an external website

Ethypharm is growing fast and is always looking to enrich its teams with new talented individuals. We encourage you to visit this site regularly and to follow Ethypharm on LinkedIn to read our latest updates and stay informed about our job opportunities.

Linked